Erica Novo

Turin, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

The role of OSM/OSMRβ axis in shaping the tumor microenvironment favoring MASLD-related HCC immune evasion.

The role of OSM/OSMRβ axis in shaping the tumor microenvironment favoring MASLD-related HCC immune evasion.

Journal: Hepatology (Baltimore, Md.)

Published: April 17, 2025

Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.

Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.

Journal: Frontiers in immunology

Published: November 21, 2023

The protease activated receptor 2 - CCAAT/enhancer-binding protein beta - SerpinB3 axis inhibition as a novel strategy for the treatment of non-alcoholic steatohepatitis.

The protease activated receptor 2 - CCAAT/enhancer-binding protein beta - SerpinB3 axis inhibition as a novel strategy for the treatment of non-alcoholic steatohepatitis.

Journal: Molecular metabolism

Published: October 27, 2023

The polymorphic variant of SerpinB3 (SerpinB3-PD) is associated with faster cirrhosis decompensation.

The polymorphic variant of SerpinB3 (SerpinB3-PD) is associated with faster cirrhosis decompensation.

Journal: Alimentary pharmacology & therapeutics

Published: February 17, 2023

Hepatic Myofibroblasts: A Heterogeneous and Redox-Modulated Cell Population in Liver Fibrogenesis.

Hepatic Myofibroblasts: A Heterogeneous and Redox-Modulated Cell Population in Liver Fibrogenesis.

Journal: Antioxidants (Basel, Switzerland)

Published: May 03, 2022

SerpinB3 as a Pro-Inflammatory Mediator in the Progression of Experimental Non-Alcoholic Fatty Liver Disease.

SerpinB3 as a Pro-Inflammatory Mediator in the Progression of Experimental Non-Alcoholic Fatty Liver Disease.

Journal: Frontiers in immunology

Published: April 01, 2022

Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis.

Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis.

Journal: The Journal of pathology

Published: August 12, 2021

Hypoxia, Hypoxia-Inducible Factors and Liver Fibrosis.

Hypoxia, Hypoxia-Inducible Factors and Liver Fibrosis.

Journal: Cells

Published: June 14, 2021

Hepatocyte-Specific Deletion of HIF2α Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation.

Hepatocyte-Specific Deletion of HIF2α Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation.

Journal: Cellular and molecular gastroenterology and hepatology

Published: May 06, 2021

HDL cholesterol protects from liver injury in mice with intestinal specific LXRα activation.

HDL cholesterol protects from liver injury in mice with intestinal specific LXRα activation.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: April 05, 2020

Liver fibrogenesis: un update on established and emerging basic concepts.

Liver fibrogenesis: un update on established and emerging basic concepts.

Journal: Archives of biochemistry and biophysics

Published: February 27, 2020

SerpinB3 Differently Up-Regulates Hypoxia Inducible Factors -1α and -2α in Hepatocellular Carcinoma: Mechanisms Revealing Novel Potential Therapeutic Targets.

SerpinB3 Differently Up-Regulates Hypoxia Inducible Factors -1α and -2α in Hepatocellular Carcinoma: Mechanisms Revealing Novel Potential Therapeutic Targets.

Journal: Cancers

Published: November 04, 2019

Showing 1-12 of 31

Last Updated: 09/26/2026